CERo Therapeutics Holdings, Inc. dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML). The first patient showed no dose-limiting toxicities and had a 20.8-fold expansion of infused cells. The study aims to evaluate safety and efficacy, with primary outcomes including adverse events and overall response rate. CEO Chris Ehrlich expressed optimism for the therapy’s potential. CERo’s unique approach to T cell engineering seeks to optimize cancer therapy by engaging the body’s immune system to eliminate tumors. The company is focused on advancing CER-1236 for hematological malignancies.

Read more at GlobeNewswire: CERo Therapeutics Doses Second Acute Myeloid Leukemia